Melanoma Stage III, Melanoma Stage IV
Conditions
Brief summary
In this study the aim is to investigate whether transfer of the microbiota of either responder or non-responder patients via fecal microbiotica transplantation (FMT) can convert the response to immunotherapy in immune checkpoint inhibitors (ICI) refractory metastatic melanoma patients. This is a randomized double-blind intervention phase Ib/IIa trial in ICI refractory metastatic melanoma patients receiving either FMT of an ICI responding or FMT from an ICI non-responding donor, in combination with ICI. Following randomization, patients will receive vancomycin 250 mg, four times daily for 4 days (day -5 up until day -2), and undergo bowel clearance on day -1 (in total 1L MoviPrep). The FMT, either derived from donor group R (who showed a good response on anti-PD-1 therapy) or donor group NR (who showed progression on anti-PD-1 therapy), will be performed by a gastroenterologist using esophagogastroduodenoscopy. A total amount of 198mL (containing a total of 60 gram feces) will be used for transplantation. Anti-PD-1 treatment will be continued according to the patient's regular treatment schedule. Evaluation of safety and response to treatment will be performed.
Interventions
OTHERFecal microbiota transplantation
Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
Sponsors
The Netherlands Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
a randomized double-blind intervention trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients should be 18 years or older * Patients have pathologically confirmed advanced stage cutaneous melanoma (stage III or IV) requiring systemic treatment with anti-PD-1 * In case of stage IV disease, only patients with M1a or M1b disease are eligible. * Patients have confirmed disease progression (≥20% increase according to RECIST1.1) on two consecutive scans with a four week interval while on anti-PD-1 treatment, of which the second scan has to be performed within 3 weeks prior to signing informed consent. * Patients must have measurable disease per RECIST 1.1 criteria * Patients have an ECOG performance status of 0-1 (appendix D) * Patients have a life expectancy of \>3 months * Patients have adequate organ function as determined by standard-of-care pre-checkpoint inhibitor infusion lab (including serum ALAT/ASAT less than three times the upper limit of normal (ULN); serum creatinine clearance 50ml/min or higher; total bilirubin less than or equal to 20 micromol/L, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 50 micromol/L) * Patients have an LDH level of ≤1 times ULN * Patients of both genders must be willing to use a highly effective method of birth control during treatment * Patients must be able to understand and sign the Informed Consent document
Exclusion criteria
* Patients with acral, uveal or mucosal melanoma, or patients with an unknown primary * Patients who have received treatment for their melanoma other than anti-PD-1 treatment. * Stage IV patients with M1c or M1d disease. * Patients with autoimmune diseases: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are excluded from this study (except Hashimoto thyroiditis, vitiligo, history of psoriasis, but no active disease) * Patients with any grade 3 or 4 immune-related adverse events still requiring active immunosuppressive medication, apart from endocrinopathies that are stable under hormone replacement therapy. Patients who had developed grade 3-4 immune related toxicity, which has reverted to grade I with immunosuppressive drugs and who are off immunosuppression at least two weeks prior to enrollment are eligible * Patients with brain or LM metastasis. * Patients with an elevated LDH level * Patients that have undergone major gastric/esophageal/bowel surgery (like Wipple, subtotal colectomy) * Severe food allergy (e.g. nuts, shellfish) * Patients with a swallowing disorder or expected bowel passage problems (ileus, fistulas, perforation) * Severe dysphagia with incapability of swallowing 2 liters of bowel lavage * Patients with a life expectancy of less than three months * Patients with severe cardiac or pulmonary comorbidities (per judgement of the investigator) * Women who are pregnant or breastfeeding * Patients with any active systemic infections, coagulation disorders or other active major medical illnesses * Patients with other malignancies, except adequately treated and a cancer-related life-expectancy of more than 5 years * Patients who received treatment with antibiotics in the three months prior to study enrolment, or patients we are expected to receive systemic antibiotics during the course of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy, defined as clinical benefit (stable disease (SD), partial response (PR), complete response (CR) | At 12 weeks after FMT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety, measured as the occurrence of toxicity of grade 3 or higher | At screening, and 2 weeks, 6 weeks, 12 weeks and 16 weeks after FMT | — |
| Progression free survival (PFS) | Up to one year post-FMT | PFS will be calculated from the date of registration to the date of progression or death, whichever occurs first, censoring patients without progression and who are still alive at last follow-up |
| The change in gut microbiome following FMT and the duration and stability over time | At screening, and 2 weeks, 6 weeks, 12 weeks and 16 weeks after FMT | To assess the fecal microbiome (which includes bacteria, archaea, viruses, parasites and fungi), nucleotides will be isolated for next generation sequencing and molecular methodologies (e.g. PCR, qPCR). Initially, whole genomic DNA (metagenomics) and the ITS2 region or the rRNA gene will be will be sequenced, giving insights in the overall microbiota's structural and functional features and in the structural features of the fungal microbiota, respectively, which both will be associated to clinical variables. |
| The change in metabolome following FMT and the duration and stability over time | At screening, and 2 weeks, 6 weeks, 12 weeks and 16 weeks after FMT | To assess the metabolome in feces (which includes amino acids, short lipids, sugars and nucleotides), samples will be processed and analyzed by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) or Nuclear magnetic resonance (NMR). The identified metabolic profile will be associated with the microbiome data and clinical variables. |
| The immune changes; changes in cell populations (absolute, relative, phenotypical), in chemokine/cytokine levels and in the tumor-microenvironment | At screening, and 2 weeks, 6 weeks, 12 weeks and 16 weeks after FMT | Tumor biopsies and blood samples will be analyzed to investigator the local and systemic immune changes: changes in cell populations (absolute, relative, phenotypical), in chemokine/cytokine levels and in the tumor-microenvironment (TME). If possible, results will be linked to response. |
Countries
Netherlands
Contacts
Primary ContactJohn Haanen, Prof
Backup ContactFemke Burgers, MD
Outcome results
None listed